Both sorafenib and mammalian target of rapamycin inhibitor (mTORi) have antitumor effects.
This study aimed to evaluate their antitumor effects in liver transplantation (LT) recipients …

There is currently no consensus on the most suitable treatment for the recurrence of
hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter …

Treatment options of recurrent hepatocellular carcinoma (HCC) after liver transplantation are
limited and data on systemic compounds for advanced tumor stages in transplant recipients …

Background. Sorafenib (SOR) is currently used for hepatocellular carcinoma (HCC)
recurring after liver transplantation (LT) when HCC is unsuitable for surgical/locoregional …

Background The role of sorafenib in patients with hepatocellular carcinoma (HCC)
recurrence after liver transplantation (LT) has been rarely studied. The aim of this study was …

Background Data on survival and safety of sorafenib for hepatocellular carcinoma
recurrence after liver transplant are still equivocal. Aim We performed a meta-analysis of …

e15579 Background: Sorafenib has been approved for the treatment of advanced HCC.
However, there is no data on its use for HCC patients (pts) after liver transplantation (OLT) …

Prevention of hepatocellular carcinoma (HCC) recurrence after liver transplantation is a
clinical priority. The importance of the mammalian target of rapamycin (mTOR) pathway in …

BACKGROUND & AIMS: The efficacy of sorafenib in the post-liver transplantation (LT)
setting has been scarcely studied. The aim of this study was to evaluate the efficacy of …

Background: Hepatocellular carcinoma (HCC) recurrence is still threatening patient survival
after liver transplantation (LT). The efficacy and safety of sorafenib in the setting of post-LT …